ZNTL

Zentalis Pharmaceuticals Inc

Aug 27 • 04:00PM ET

1.82

Dollar change -0.03
Percentage change -1.62	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN

| Held by: VTI VXF SCHA PRFZ FESM IWC VHT DFAS FSCC BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	20.68%	Shs Outstand	72.14M	Perf Week	10.98%
Market Cap	131.29M	Forward P/E	-	EPS next Y	-2.07	Insider Trans	0.14%	Shs Float	57.22M	Perf Month	34.81%
Enterprise Value	-130.82M	PEG	-	EPS next Q	-0.53	Inst Own	73.30%	Short Float	7.80%	Perf Quarter	45.60%
Income	-162.78M	P/S	4.89	EPS this Y	7.24%	Inst Trans	-6.14%	Short Ratio	4.49	Perf Half Y	-15.35%
Sales	26.86M	P/B	0.48	EPS next Y	4.44%	ROA	-38.60%	Short Interest	4.46M	Perf YTD	-39.93%
Book/sh	3.81	P/C	0.43	EPS next 5Y	8.39%	ROE	-49.55%	52W High	5.44 -66.54%	Perf Year	-42.95%
Cash/sh	4.21	P/FCF	-	EPS past 3/5Y	14.39% -12.89%	ROIC	-52.14%	52W Low	1.01 80.20%	Perf 3Y	-93.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.05%	Volatility	12.93% 8.06%	Perf 5Y	-94.79%
Dividend TTM	-	EV/Sales	-4.87	EPS Y/Y TTM	17.10%	Oper. Margin	-633.83%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.99	Sales Y/Y TTM	-33.76%	Profit Margin	-605.93%	RSI (14)	63.98	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	7.99	EPS Q/Q	69.96%	SMA20	16.00%	Beta	1.78	Target Price	6.19
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	26.99%	Rel Volume	0.78	Prev Close	1.85
Employees	166	LT Debt/Eq	0.14	Earnings	Aug 06 AMC	SMA200	-8.05%	Avg Volume	994.34K	Price	1.82
IPO	Apr 03, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.67% -	Trades		Volume	773,766	Change	-1.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral	$4
Jun-20-24	Downgrade	UBS	Buy → Neutral	$28 → $5
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform	$15 → $4
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $8
Jun-18-24	Downgrade	Jefferies	Buy → Hold	$42 → $6
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45
Apr-28-20	Initiated	Jefferies	Buy	$41

Show Previous Ratings

Aug-26-25 04:05PM	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Aug-06-25 04:05PM	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.07%
Jul-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.88%
05:00PM	Loading…
May-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC (GlobeNewswire)
Apr-23-25 04:05PM	Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-01-25 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.58%
Mar-26-25 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -5.88%
Mar-25-25 04:40PM	Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.56%
Mar-15-25 11:25AM	Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Mar-03-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.25%
08:00AM	Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Feb-24-25 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
12:21AM	Loading…
Feb-21-25 12:21AM	Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey) -6.07%
Feb-03-25 05:42PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:35AM	Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-30-25 10:20AM	Zentalis price target lowered to $10 from $20 at Oppenheimer (TipRanks) -12.17%
Jan-29-25 07:00AM	Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer (GlobeNewswire) -21.25%
Jan-28-25 04:05PM	Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development (GlobeNewswire)
Jan-09-25 12:00PM	Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies (GlobeNewswire)
Jan-02-25 04:53PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
Dec-12-24 07:00AM	Zentalis Pharmaceuticals Announces Key Management Appointments (GlobeNewswire) -10.57%
Dec-02-24 04:35PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Nov-13-24 08:00AM	Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib (GlobeNewswire) +5.66%
Nov-01-24 07:04PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings (GuruFocus.com)
Oct-07-24 03:03PM	FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc (GuruFocus.com) -7.72%
12:15PM	Loading…
Sep-17-24 12:15PM	FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor (Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM	FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers (Benzinga) +13.58%
07:00AM	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies (GlobeNewswire)
Sep-09-24 07:00AM	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 (GlobeNewswire)
Sep-03-24 04:40PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.92%
Aug-26-24 11:58AM	Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why (Zacks)
Aug-09-24 02:53PM	ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 (InvestorPlace) -9.37%
07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
Aug-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.00%
Jul-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.80%
Jun-19-24 10:23AM	Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold (Zacks)
04:52AM	FDA places partial clinical hold on Zentalis trials of azenosertib for cancer (Clinical Trials Arena)
Jun-18-24 07:00AM	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program (GlobeNewswire) -50.66%
Jun-03-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-24 02:43AM	Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ... (GuruFocus.com)
May-30-24 07:00AM	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors (GlobeNewswire)
May-23-24 05:01PM	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.84%
May-14-24 07:00AM	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-08-24 10:27AM	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating (MT Newswires)
May-07-24 09:04PM	Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ... (GuruFocus.com) +5.03%
01:54PM	ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
May-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 04:05PM	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 (GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:55AM	Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet (Zacks) +5.30%
07:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 07:01PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... (GuruFocus.com)
07:00AM	Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Feb-14-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL) (Zacks) +10.34%
Feb-13-24 07:00AM	Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) -5.83%
Feb-08-24 12:00PM	What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock (Zacks)
Feb-05-24 11:26PM	Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Feb-01-24 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-24 07:00AM	Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments (GlobeNewswire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.15%
Jan-02-24 04:49PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.54%
Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com) +14.42%
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20% -18.27%
07:18AM	Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-01-23 04:52PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-23 05:00AM	Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ... (GuruFocus.com)
Oct-02-23 04:27PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-23 01:02AM	Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Sep-06-23 07:00AM	Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Sep-01-23 04:37PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.34%
Aug-09-23 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-23 04:28PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer (GlobeNewswire)
Jun-15-23 06:01AM	Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire) +12.67%
Jun-06-23 06:00AM	Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing (GlobeNewswire)
Jun-02-23 02:34PM	Why Shares of Zentalis Pharmaceuticals Dropped This Week (Motley Fool)
May-26-23 12:33PM	Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside (TipRanks) +10.64%
10:53AM	Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes (Benzinga)
May-25-23 05:38PM	Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting (GlobeNewswire)
May-23-23 07:00AM	Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations (GlobeNewswire)
May-12-23 09:55AM	Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade (Zacks)
May-10-23 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates (GlobeNewswire) +6.93%
Apr-26-23 10:00AM	Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-17-23 09:00AM	Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023 (GlobeNewswire) +7.51%
Mar-01-23 07:00AM	Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates (GlobeNewswire)
Feb-13-23 07:00AM	Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer (GlobeNewswire)
Feb-01-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:01AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:18AM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely (Simply Wall St.)
Jan-03-23 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Myers Scott Dunseth	Director	Apr 30 '25	Buy	1.40	21,000	29,373	281,192	Apr 30 05:07 PM
Bruns Ingmar	Chief Medical Officer	Feb 06 '25	Buy	2.28	20,000	45,656	36,629	Feb 12 05:00 PM
Cam Gallagher	Former Director	Feb 11 '25	Proposed Sale	2.00	687	1,374		Feb 11 08:06 PM
Vultaggio Vincent	PAO and Interim PFO	Feb 03 '25	Sale	1.71	2,615	4,476	189,826	Feb 05 06:33 PM
Lackner Mark	Chief Scientific Officer	Feb 03 '25	Sale	1.71	14,368	24,591	512,856	Feb 05 06:32 PM
Paul Andrea	Chief Legal Officer	Feb 03 '25	Sale	1.71	13,230	22,643	1,070,784	Feb 05 06:31 PM
Skvarka Jan	Director	Jan 31 '25	Buy	1.72	60,000	103,446	149,551	Feb 04 04:45 PM
Walker Luke Nathaniel	Director	Jan 31 '25	Buy	1.76	14,200	24,966	86,681	Feb 04 04:43 PM
EASTLAND JULIA MARIE	CEO & President	Jan 31 '25	Buy	1.73	28,500	49,345	28,500	Feb 04 04:37 PM
Mark Lackner	Chief Scientific Officer	Feb 03 '25	Proposed Sale	1.71	14,368	24,591		Feb 03 07:14 PM
Andrea Paul	Chief Legal Officer & Corporat	Feb 03 '25	Proposed Sale	1.71	13,230	22,643		Feb 03 07:13 PM
Cam Gallagher	Former Director	Feb 03 '25	Proposed Sale	1.71	28,558	48,877		Feb 03 07:12 PM
Lackner Mark	Chief Scientific Officer	Jan 02 '25	Sale	3.12	4,411	13,762	191,317	Jan 03 05:17 PM
Diana Hausman	Former Chief Medical Officer	Oct 31 '24	Proposed Sale	2.86	9,888	28,294		Oct 31 08:59 PM
Vultaggio Vincent	Principal Accounting Officer	Oct 04 '24	Sale	3.18	1,603	5,098	33,855	Oct 04 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZNTL

Zentalis Pharmaceuticals Inc

Upgrade your FINVIZ experience